EMA greenlights 15 new meds

The EMA’s human medicines committee (CHMP) recommended fifteen medicines for approval at its January 2020 meeting.

Read more

Sleeping sickness target deciphered

Researchers at the University of Luebeck have revealed the structure of the IMP dehydrogenase, a central target of T. brucei, which causes sleeping sickness.

Read more

UK researchers present dengue virus transmission map

Scientists at Imperial College London have created a worldwide atlas of dengue virus transmission with much higher spatial resolution than any previous regional- or global-scale estimates.

Read more

AMR: IMI’s Enable project reaches endpoints

The ENABLE project has achieved its initial goals to identify three antibacterial leads, select two antibacterial development candidates and advance one compound into Phase I development.

Read more

MercachemSyncom, Bionetix, and ProQinase ink AML contract

Bionetix, ProQinase, and MercachemSyncom have announced that they will jointly develop a new AML drug, from target identification to clinical testing

Read more

iOnctura SA bags €15m in Series A round

Merck KGaA’s 2017 Swiss cancer spin-out iOnctura SA has raised €15m to bring its PI3K? inhibitor and autotaxin inhibitor to the clinic.

Read more

BioNTech acquires Neon at cheapest for $67m

mRNA cancer neoantigen specialist BioNTech AG is set to buy all shares of Neon Therapeutics, Inc. expanding its pipeline of neoantigen-targeting therapies and getting foothold in the US.

Read more

New stromal target overcomes cancer resistance

British researchers have identified several small molecule drugs that sensitized B cell cancers to chemotherapy and extended survival in mouse models.

Read more

Astellas and Adaptimmune team up in CAR-T development

Adaptimmune Therapeutics plc and Japanese Astellas Pharma, Inc. have signed a discovery partnership to develop off-the-shelf allogeneic T cell-based cancer therapies from stem cells.

Read more

Illumina embraces Roche

Twelve years after Roche’s $6.8bn hostile takeover bid for Illumina, the companies have entered into a 15-year partnership to boost personalised NGS-based cancer testing.

Read more